Łuszczyca: badanie fazy III leku guselkumab
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Badania kliniczne w Polsce, do których mogą być włączone dzieci i młodzież poniżej 18 lat. Udział dziecka zawsze wymaga zgody rodziców lub opiekunów, a starsze dzieci wyrażają też własną zgodę.
387 badań w Polsce: 346 rekrutuje, 41 wkrótce zacznie. Ośrodki w 79 miastach.
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
A Randomised, Controlled, Double-blinded, Multi-country, Multi-centre Trial to Study Growth and Health Outcomes of a New Infant- and follow-on Formula for Healthy Term Infants.
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
Cardioneuroablation: Fragmented Atrial Potentials, Intracardiac Echocardiography and Computed Tomography
Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With…
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Cardioneuroablation and Ventricular Proarrhythmia
A long-term, double-blind, randomised, placebo-controlled clinical trial to investigate the efficacy and safety of PQ Grass 27600 SU in children and adolescents with seasonal…
The Effect of a Multispecies Probiotics on Autism Symptoms in Children
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU)…
Music Therapy Songwriting and Mental Health in Neonatel Intensive Care Unit (NICU) Parents
Polish Infants and Toddler Nutritional Study
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Assessment of the safety and effectiveness of vedolizumab induction therapy compared to standard infliximab therapy in pediatric patients with ulcerative colitis "VEDI-UC”
Is Feeding During Therapeutic Hypothermia Safe and Can Improve Outcomes in Infants With Hypoxic-ischaemic Encephalopathy
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Anti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Efficacy of Cashew Nut Protein Immunotherapy
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients
An open-label Extension study to evaluate rozanolixizumab in pediatric study participants with generalized myasthenia gravis
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine…
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Zadzwoń i porozmawiaj z doradcą ds. badań klinicznych. Sprawdzimy w rejestrach, do których badań możesz się kwalifikować.
Nie udzielamy porad ani konsultacji medycznych. Pomagamy znaleźć badanie i skontaktować się z ośrodkiem.
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 3 października 2026.